期刊文献+

宫颈特殊染色法联合人乳头状瘤病毒E6/E7 mRNA与液基薄层细胞学检查在宫颈癌筛查中的诊断价值 被引量:10

Diagnostic value of cervical special staining combined with human papillomavirus E6/E7 mRNA and thinprep cytologic test in cervical lesions screening
原文传递
导出
摘要 目的探究宫颈特殊染色法(FRD)联合高危型人乳头状瘤病毒(HPV)E6/E7 mRNA与液基薄层细胞学(TCT)在宫颈癌筛查中的诊断价值。方法选取2018年10月至2019年11月在萧山医院行宫颈癌筛查的734例疑似宫颈癌患者作为研究对象,进行FRD、HPV E6/E7 mRNA和TCT检测。以阴道镜取样活组织检查作为金标准,对比以上检测手段单独检测及联合检测对宫颈癌的诊断效能。结果734例疑似宫颈癌患者中,病理活组织检查阳性率为9.81%(72例);FRD阳性率为11.99%(88例),HPV E6/E7 mRNA阳性率为12.53%(92例),TCT阳性率为14.44%(106例),符合率分别为93.46%、92.37%和89.92%,FRD、HPV E6/E7 mRNA与病理学诊断结果的Kappa值分别为0.664和0.616,TCT与病理学诊断结果的Kappa值为0.529。FRD、HPV E6/E7 mRNA和TCT的灵敏度分别为77.78%、75.00%和72.22%,且3种方法联合检查的灵敏度为95.83%,优于单独检查。结论FRD在宫颈癌筛查方面具有与TCT、HPVE6/E7 mRNA相仿的效能,且与TCT、HPV E6/E7 mRNA联合应用有助于提高灵敏度,加之具有快捷和成本低的特点,有一定的推广意义。 Objective To explore the diagnostic value of cervical special staining(FRD)combined with high-risk HPV E6/E7 mRNA and thinprep cytologic test(TCT)in cervical lesions screening.Methods A total of 734 women who underwent cervical lesions screening in Xiaoshan Hospital from October 2018 to November 2019 were enrolled for FRD,HPV E6/E7 mRNA and TCT detection.Colposcopy sampling and biopsy was taken as the gold standard.The diagnostic efficacy of the above detection methods and combined detection in cervical lesions was compared.Results In 734 patients with suspected cervical lesions,the positive rates of pathological biopsy,FRD,HPV E6/E7 mRNA and TCT were 9.81%(72 cases),11.99%(88 cases),12.53%(92 cases)and 14.44%(106 cases),respectively.The coincidence rates were 93.46%,92.37%and 89.92%,respectively.The Kappa coefficients between FRD,HPV E6/E7 mRNA and pathological diagnosis were 0.664 and 0.616,respectively.The Kappa coefficient between TCT and pathological diagnosis was 0.529.The sensitivities of FRD,HPV E6/E7 mRNA and TCT were 77.78%,75.00%and 72.22%,respectively.The sensitivity of joint detection of three methods was 95.83%,which was better than that of separate detection.Conclusions FRD has the similar diagnostic efficacy with TCT and HPV E6/E7 mRNA,and is conducive to improve sensitivity combined application with TCT and HPV E6/E7 mRNA.Added to the advantages of rapidness and low cost,it has higher promotion significance.
作者 朱郑霞 寿坚 Zhu Zhengxia;Shou Jian(Department of Obstetrics and Gynecology,Xiaoshan Hospital,Hangzhou 311201,China;Department of Gynecology,Xiaoshan Hospital,Hangzhou 311201,China)
出处 《国际流行病学传染病学杂志》 CAS 2021年第5期380-383,共4页 International Journal of Epidemiology and Infectious Disease
基金 杭州市卫生科技计划(2017B25)。
关键词 宫颈肿瘤 宫颈特殊染色法 E6/E7 mRNA 液基薄层细胞学 人乳头瘤病毒 联合诊断 灵敏度 Uterine cervical neoplasms Special staining of cervix E6/E7 mRNA Thinprep cytologic test Human papillomavirus Joint detection Sensitivity
  • 相关文献

参考文献8

二级参考文献82

  • 1杨瑞,王淑君,张颖.亚甲蓝作为淋巴示踪剂的研究与展望[J].中国药剂学杂志(网络版),2009(2):65-71. 被引量:16
  • 2杨英捷,赵健,李雪倩,廖秦平.2285例女性下生殖道人乳头状瘤病毒感染筛查结果分析[J].中国实用妇科与产科杂志,2006,22(6):444-445. 被引量:95
  • 3Jemal A,Siegel R,Ward E. Cancer Statistics,2007[J].{H}CA-A Cancer Journal for Clinicians,2007.43-66.
  • 4Howe HL,Wu X,Ries LA. Annual report to the nation on the status of cancer,1975-2003,featuring cancer among U.S.Hispanic/Latino populations[J].{H}CANCER,2006,(08):1711-1742.
  • 5Sherman ME,Wang SS,Carreon J. Mortality trends for cervical squamous and adenocarcinoma in the United States.Relation to incidence and survival[J].{H}CANCER,2005,(06):1258-1264.
  • 6Parkin DM,Bray F,Ferlay J. Global cancer statistics,2002[J].{H}CA-A Cancer Journal for Clinicians,2005.74-108.
  • 7Kamangar F,Dores GM,Anderson WF. Patterns of cancer incidence,mortality,and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world[J].{H}Journal of Clinical Oncology,2006,(14):2137-2150.
  • 8Villa LL,Costa RL,Petta CA. Prophylactic quadrivalent human papillomavirus(types 6,11,16,and 18)L1 virus-like particle vaccine in young women:a randomized double-blind placebo-controlled multicentre phase II efifcacy trial[J].{H}LANCET ONCOLOGY,2005.271-278.
  • 9Ault KA,Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2,grade 3,and adenocarcinoma in situ:a combined analysis of four randomised clinical trials[J].{H}LANCET,2007,(9576):1861-1868.
  • 10FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions[J].{H}New England Journal of Medicine,2007,(19):1915-1927.

共引文献417

同被引文献99

引证文献10

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部